Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

• DOI: 10.1111/ceo.14054
• Publication Date: 2022-02-02T07:54:09Z
• Authors: Javier Zarranz‐Ve...; Alba Parrado‐Carr...; Vuong Nguyen; Laura Sararols; Gonzaga Garay‐Ara...; Martín Puzo; Carolina Arruabar...; Marc Figueras‐Roca; Mark C. Gillies; Ricardo P. Casaro...
• Keywords: Aflibercept

To study the visual outcomes of neovascular AMD (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs at national level.Multicenter database nAMD eyes anti-VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat-and-extend (TAE) regimens. Demographics, acuity (VA) logarithm minimum angle resolution (logMAR) ETDRS letters baseline and subsequent visits, number visits data were collected using a validated web-based tool (Fight Retinal Blindness!).1273 (1014 patients) included, 971 treatment naïve (TN) 302 previously (PT). Baseline VA (mean ± SD) was 57.5 (±19.5) 62.2 (±17) (p > 0.001), 24 months final 60.4 (±21.2) 58.8 (±21.1) = 0.326), respectively. Mean change 12/24 +4.2/+2.9 TN +0.1/-3.4 PT < 0.001/p 0.001). The percentage ≥15 gainers/losers 24.8%/14.5% TN, 10.3%/15.7% eyes. median injections/visits 12 7/9 6/8 0.002/p 0.001) 11/16 11/14 0.329/p Study included ranibizumab (39.5%), aflibercept (41.2%) bevacizumab (19.3%).Independent, large-scale audits are feasible if committed health care professionals provided efficient information technology systems to do them. results described here represent an adequate measurement quality delivered nationwide benchmark clinical management country level compared other real-world international cohorts.